drugset / Trial / NCT03491579
Epacadostat, Cladribine and Cytarabine (ECC) in AML
NaSingle-groupOpen-labelTreatment
Summary
This trial assess the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of epacadostat when added to the cladribine/cytarabine chemotherapy in relapsed / refractory AML patients fit for intensive treatment
Timeline
- Start
- 2018-12
- Primary completion
- 2019-09
- Completion
- 2019-10
Outcome
Outcome not reported
Stopped: “IMP will not be further developed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epacadostat | Small molecule | — | Oral |
| Background | Cladribine | Small molecule | — | — |
| Background | Cytarabine | Small molecule | — | — |